Assembling evidence grade
Loading
Independent evidence before payment.
Oral GH secretagogue (non-peptide) · also: Ibutamoren, MK-0677
MK-677 carries an Evidence Grade of B (Medium confidence). The strongest published evidence catalogued is human rct / review.
Grade B rule: One human RCT, Phase-2-only RCTs, or three or more other human studies.
The grade reflects the strength of the published evidence, not safety or efficacy. “Confidence” means how settled that grade is given the record — not how likely the compound is to work.
Human-use stop
This compound is investigational, warned or not approved for human use. A seller calling it “research only,” showing testimonials, registering a company or publishing a COA does not create an approved consumer medicine. Seller links below are market-surveillance records, not recommendations.
MK-677 (ibutamoren) is an orally active growth-hormone secretagogue studied in several human trials, including in older adults and for GH/IGF-1 response.
Animal and in-vitro results are shown separately and must never be read as established human outcomes.
In plain terms: there are 2 randomised human trials here — the strongest kind of evidence. That is about the research, not about any particular seller or batch.
Strongest: randomised or pooled human trials.
MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study. Archives of gerontology and geriatrics, 2011.
MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. The Journal of clinical endocrinology and metabolism, 1998.
Observational, open-label or small human studies.
LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report. Experimental physiology, 2022.
Preclinical animal models — not a human outcome.
Insulin-like growth factor-1 and growth hormone (GH) levels in canine cerebrospinal fluid are unaffected by GH or GH secretagogue (MK-0677) administration. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 1999.
Cell / tissue studies — not a human outcome.
Equine metabolism of the growth hormone secretagogue MK-0677 in vitro and in urine and plasma following oral administration. Drug testing and analysis, 2022.
Proposed mechanism — hypothesis, not evidence of effect.
Knowing the minimal detectable dose can facilitate the interpretation of a hair test result: II. Case example with ibutamoren (MK-677), a growth hormone secretagogue. Clinica chimica acta; international journal of clinical chemistry, 2026.
Hepatotoxicity induced by MK-677. BMJ case reports, 2025.
Detection of the growth hormone secretagogue MK-0677 in equine hair following oral administration. Drug testing and analysis, 2023.
Characterization of growth hormone secretagogue small molecule ibutamoren (MK-0677) and its possible metabolites in thoroughbred horses for doping control. Rapid communications in mass spectrometry : RCM, 2022.
Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational andrology and urology, 2020.
The Safety and Efficacy of Growth Hormone Secretagogues. Sexual medicine reviews, 2018.
Growth hormone-releasing peptides. European journal of endocrinology, 1997.
On “cited by N”: citation counts (Crossref) reflect how often a paper has been referenced — a measure of academic attention, not of validity, safety, or whether a compound works. They do not affect the Evidence Grade, which is set purely by the strength of the evidence tier.
Despite human data, it remains investigational with no marketing authorisation; some trials noted metabolic effects to weigh.
Not an approved medicine in major markets. Sold only as a “research chemical”, with no established safe consumer use, dose or supply standard.
PepCred flags any vendor selling this compound to the public as a consumer-protection concern. Status reflects regulator records; see the regulatory detail below.
Registered studies:
No FDA-approved (US) drug labelling found for this compound. A search of openFDA returned no approved product containing it as an active ingredient.
This reflects US FDA approval only — other regulators (e.g. MHRA, EMA) may differ; see the note below. Absence of an approved label is not, by itself, a safety finding, and a “research use only” label does not establish safety, legality or correct identity.
PepCred note: Investigational — not approved.
These unranked records show where the name was detected. For an investigational, warned or unapproved compound, no seller, company registration, review score or COA creates an approved human-use route.
None of these is verified for human use.